When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HRTX - Heron Therapeutics: Generic Competition And HTX-011 Approval May Put Pressure On Share Price
Heron Therapeutics Inc.
Investment Thesis
Heron Therapeutics (HRTX) had a mixed year in 2019 and in my view some of the problems the company encountered are likely to continue to be felt through 2020 and perhaps beyond. This makes me concerned for the price of the company's stock.
The three main issues the company faces are the FDA's rejection of Heron's NDA for extended release local anaesthetic HTX-011, the decline in sales of Sustol, approved for the treatment of chemotherapy-induced nausea and vomiting ("CINV"), owing to competition from generics, and the possible decline in sales of